Head to head
BPC-157 vs TB-500: Repair Peptides Compared
Published by Peptara Labs · Updated · How we research and check our pages
BPC-157 vs TB-500: a side-by-side comparison of the two recovery peptides most often discussed together: mechanism, injury type, what the research used, side effects, price per vial and per mg, and the KLOW Combo option. Both BPC-157 and TB-500 are research compounds, not FDA-approved for any indication, and neither has a human dosing trial.
Verdict in 4 lines
- Both are research peptides studied for tissue repair; neither is FDA-approved.
- BPC-157 research, mostly rat studies, centers on gut, tendon, and ligament injury, with pro-angiogenic and cytoprotective mechanisms proposed.
- TB-500 comes from thymosin beta-4, which binds actin and drives cell migration; its research is skin wound and corneal repair in mice.
- No study has tested the two together. Peptara also sells both inside the KLOW Combo (BPC-157, TB-500, GHK-Cu, and KPV in one vial).
TL;DR comparison
One table, every row that matters. The recon row assumes the Peptara standard reconstitution (BPC 20mg and TB-500 10mg, each in 2mL bac water; BPC gives 0.1mg per unit, TB-500 0.05mg per unit on a U-100 syringe). That is vial arithmetic, not a dose. See the reconstitution guide for the underlying math.
Mechanism: pro-angiogenic vs actin-sequestering
Both peptides are studied for tissue repair in animals, through different molecular routes. That difference is why they are so often discussed together.
BPC-157 (pro-angiogenic)
A 15-amino-acid fragment derived from a protective gastric juice peptide. In animal and cell studies it is linked to blood vessel growth (angiogenesis) at the injury site, lower inflammation, and fibroblast activity. The published evidence is in rodent models of gut, tendon, and ligament injury (Sikiric et al series).
View BPC-157 product
TB-500 (actin-sequestering)
A synthetic fragment of thymosin beta-4, the body's own regulator of actin polymerization. Binds and sequesters G-actin, which controls how migrating cells move into a wound bed. Studied in wound healing and anti-fibrotic processes (Goldstein et al., 2012). Human evidence is limited; much of what circulates is athlete anecdote and case reports.
The proposed mechanisms differ rather than compete. In animal studies BPC is linked to new blood vessel growth and lower inflammation, while thymosin beta-4 moves repair cells into a wound (Goldstein et al., 2012). That difference is why the two are so often discussed together, although no study has tested them as a pair.
What each is discussed for, by injury type
What each compound is discussed for. Neither is an approved treatment for any of these, and neither has a human trial for them.
BPC-157 is discussed for
- Gut issues (IBD-type symptoms, leaky gut)
- Tendinopathy (golfer-elbow, patellar tendon)
- Ligament sprains
- Joint pain
- Skin healing, cuts, surgical scars
TB-500 is discussed for
- Muscle tears, strains, deep bruising
- Post-surgical recovery (muscle bias)
- Chronic muscle pain
- Systemic fatigue with soft-tissue component
- Athletes in heavy training blocks
Both are discussed for
- Chronic multi-tissue injuries
- Athletes in heavy training blocks
- Post-surgical with muscle + connective involvement
Research evidence
What is published, what is anecdotal, and the disclaimer that has to come with both.
BPC-157 evidence base
The largest body of published preclinical data comes from the multi-decade Sikiric et al rodent series, covering gastric ulcer healing, tendon-to-bone reattachment, ligament repair, and CNS effects. Smaller groups have replicated parts of the gut and tendon findings. Human controlled trials are limited and small. The peptide community references the rodent literature heavily.
TB-500 evidence base
Thymosin beta-4 (the parent molecule) has a real research literature in cardiac remodeling and wound healing. TB-500 specifically (the synthetic 7-amino-acid active fragment) has fewer controlled studies; most of its user-facing reputation comes from veterinary use (racehorses) and athlete case reports. No human trial has set a dose for TB-500 or for BPC-157.
Regulatory disclaimer
BPC-157 and TB-500 are both classified as research compounds in most jurisdictions. Neither is FDA-approved for any indication. The mechanisms and use cases described on this page come from preclinical research, peptide community case reports, and athlete anecdote, not from large randomized clinical trials. Peptara Labs sells both as research material, with Certificates of Analysis published for released batches.
Side effects
Human safety data for both are thin and mostly anecdotal, because neither has a human safety trial. Notes below are not exhaustive.
Shared
- Occasional injection-site irritation, reported anecdotally
- Occasional fatigue or light-headedness, reported anecdotally
- Any unexpected symptom is a reason to stop and see a physician
BPC-157 specific
- Mild GI changes, reported anecdotally
- No human safety trial: the evidence is rat and cell research (Drmic et al., 2018; Chang et al., 2014)
- Angiogenesis caution: anyone with a cancer history should raise it with a physician first
TB-500 specific
- Theoretical concern about cell proliferation, because thymosin beta-4 promotes cell migration and new blood vessel growth (Goldstein et al., 2012)
- No human safety trial: the evidence is thymosin beta-4 research in mice (Sosne et al., 2002; Philp et al., 2003)
- WADA-banned in competitive sport: check sport-specific regulations
What the research used, and why neither has a human dose
No human trial has set a dose, a schedule, or a cycle for BPC-157 or TB-500. The studies behind both are animal and cell research, and none of them gives a figure that carries over to a person.
| Study | Compound | Model | How it was given | What was reported |
|---|---|---|---|---|
| Drmic et al., 2018 | BPC-157 | Rats with a surgically perforated cecum | A bath of BPC-157 over the injury | More blood vessels at the wound, a narrower defect, and shorter bleeding than saline |
| Chang et al., 2014 | BPC-157 | Rat Achilles tendon cells in a dish | Added to the cell culture | More growth hormone receptor in the cells |
| Sosne et al., 2002 | Thymosin beta-4 (parent of TB-500) | Mice with a chemical burn to the cornea | Applied to the eye | Faster regrowth of the corneal surface and less inflammation |
| Philp et al., 2003 | Thymosin beta-4, and a seven-amino-acid peptide copying its actin-binding site | Skin wounds in diabetic mice and in aged mice | Applied to the wound | Faster wound repair; the short peptide also promoted repair in the aged mice |
The amounts that circulate online for either compound come from community practice, not from these studies, so this page does not repeat them. For what the animal literature reports, see BPC-157 dosage: what the research reports and TB-500 dosage: what the research reports.
Vial math (a label, not a dose)
A 20mg BPC-157 vial mixed with 2mL of bacteriostatic water gives 200 units on a U-100 syringe, so each unit holds 0.1mg. A 10mg TB-500 vial mixed the same way gives 0.05mg per unit. That arithmetic describes the vial. It is not an amount to draw, and the reconstitution guide shows the same math for other vial sizes and water volumes (1 unit equals 0.01mL on an insulin syringe).
Price per vial and per mg at Peptara
A BPC-157 vial is $117 with email signup and a TB-500 vial is $187. Per milligram, that is $5.85 for BPC-157 and $18.70 for TB-500 at the email-signup rate, with retail prices in each card below.
The arithmetic, with the amount left blank
cost of N mg = N x price per mg; weeks per vial = vial mg / N mg per week
This page leaves N blank. No human trial has set an amount for either compound, and choosing one for a reader would be dosing advice, which Peptara does not give.
BPC-157
20mg vial
- Per vial: $117 with email signup, $138 retail
- Per mg: $5.85 with email signup, $6.90 retail
TB-500
10mg vial
- Per vial: $187 with email signup, $220 retail
- Per mg: $18.70 with email signup, $22 retail
KLOW Combo
80mg vial, four peptides
- Per vial: $178 with email signup, $210 retail
- The 80mg is the combined weight of BPC-157, TB-500, GHK-Cu, and KPV, so its price per mg is not comparable to a single-compound vial.
Prices are the current catalog prices. For the full breakdown, see the BPC-157 price per vial and TB-500 price per vial pages.
Separate vials or the KLOW Combo: how the formats differ
Unlike Retatrutide vs Tirzepatide, where the two are alternatives, BPC-157 and TB-500 are often discussed together. No study has tested them as a pair, so the difference between the formats below is contents and price, not a studied outcome.
BPC-157 on its own
- One compound per 20mg vial
- Research centers on gut, tendon, and ligament models in rats
- BPC-157 product page
TB-500 on its own
- One compound per 10mg vial
- Research is thymosin beta-4 wound and corneal repair in mice
- TB-500 product page
KLOW Combo
- BPC-157, TB-500, GHK-Cu, and KPV in one 80mg vial
- Each component is studied separately; the blend has no published trial
- KLOW Combo product page
The KLOW Combo is one 80mg vial containing BPC-157, TB-500, GHK-Cu, and KPV, at $178 with email signup ($210 retail). Its ratio is fixed by the blend, so the amount of each peptide in it is set by the vial rather than chosen separately.
Frequently asked questions
Is BPC-157 or TB-500 better for tendon injuries?
BPC-157 has the stronger published evidence for tendon and ligament healing, most notably from the Sikiric et al rodent series on tendon-bone and tendon-tendon injuries, and one cited cell study found it raised growth hormone receptor expression in rat Achilles tendon cells (Chang et al., 2014). TB-500 is more often discussed for muscle and deep soft-tissue repair than for tendons specifically. Neither has a human trial for any tendon injury, so neither is an established treatment for one.
Can I stack BPC-157 and TB-500 together?
No study has tested BPC-157 and TB-500 together, so there is no studied way to combine them and this page does not offer one. They are often paired because their proposed mechanisms differ: BPC-157 is studied for angiogenesis and cytoprotection in rats (Drmic et al., 2018), while thymosin beta-4, the parent of TB-500, binds actin and drives cell migration (Goldstein et al., 2012). Peptara also sells the KLOW Combo, a single 80mg vial containing BPC-157, TB-500, GHK-Cu and KPV; the blend itself has no published trial.
Which has more published research?
BPC-157 has more published preclinical research, primarily the multi-decade Sikiric et al rodent series covering gut, tendon, ligament, and CNS effects. TB-500 has fewer published controlled studies in humans; most of the user-facing evidence is athlete anecdote and case reports. Neither peptide has large-scale randomized human trials. Both are sold as research material, with Certificates of Analysis published for released batches.
Do they have side effects?
Human safety data for both are thin and mostly anecdotal, because neither has a human safety trial. Reported effects for BPC-157 include occasional injection-site irritation and mild GI changes. For TB-500 there is a theoretical concern about cell proliferation, since its parent protein promotes cell migration and the growth of new blood vessels (Goldstein et al., 2012). TB-500 is WADA-banned in competitive sport, so athletes need to check sport-specific regulations. Any unexpected symptom is a reason to stop and see a physician.
How long should I cycle each one?
There is no studied cycle for either. No human trial has tested a BPC-157 or TB-500 schedule, and the cycle lengths quoted online come from community practice rather than research. The published evidence is rat and cell work for BPC-157 (Drmic et al., 2018; Chang et al., 2014) and thymosin beta-4 work in mice for TB-500 (Sosne et al., 2002; Philp et al., 2003). Any schedule is a decision for a licensed clinician.
Are BPC-157 or TB-500 FDA-approved?
Neither is FDA-approved for any indication. Both are classified as research compounds in most jurisdictions. Mechanisms and use cases described on this page come from preclinical research, peptide community case reports, and athlete anecdote, not from large randomized clinical trials. Peptara Labs sells both as research material, with Certificates of Analysis published for released batches.
Why are BPC-157 and TB-500 always compared?
They are the two research peptides most often discussed for tissue repair, and their proposed mechanisms do not overlap. BPC-157 research centers on gut, tendon and ligament injury in rats, while thymosin beta-4, the parent of TB-500, binds actin and drives cell migration in wound repair (Goldstein et al., 2012). Comparing them usually comes down to which tissue a research question is about. No study has tested one against the other or the two together.
What is the KLOW Combo and how is it different?
KLOW is Peptara’s four-peptide single-vial product: BPC-157, TB-500, GHK-Cu (a copper tripeptide studied for skin and collagen) and KPV (an anti-inflammatory tripeptide) in one 80mg vial, at $178 with email signup ($210 retail). The four are studied separately, and the combination itself has no published trial. Separate vials and the blend differ in format and price, not in any studied outcome.
Next steps
Buy BPC-157
20mg vial, $117 with email signup ($138 retail). Pentadecapeptide studied for gut, tendon, and ligament repair in animals. COA on the certificates page.
View product
Reconstitution math
4-step method, units-not-mL formula, calculator for the catalog vials. The arithmetic behind every unit figure, for any vial size and water volume.
Open guide
Retatrutide vs Tirzepatide
The other head-to-head in the catalog: two GLP-1-class research compounds compared on trial data and price.
Open comparison
Looking for TB-500 directly? See the TB-500 product page, or the KLOW Combo for the four-peptide vial.
Order tested material with its batch certificate
Order BPC-157, TB-500 or KLOW: third-party tested material, its batch certificate, and bac water sized to the vial.
Your kit includes the vials and bacteriostatic water. Insulin syringes ship with your order to select delivery regions; where they can't ship, we send a same-day sourcing link. A printed reference guide ships with every order. We confirm exactly what is included with your order. Order support is on WhatsApp.